Massachusetts-based pharmaceutical company Biogen Idec has agreed to acquire UK based Convergence Pharmaceuticals (CP).
CP is a clinical-stage biopharmaceutical company and the acquisition is centered on a drug it is testing that is for treating a chronic pain disease called trigeminal neuralgia ,which consists of episodic, debilitating facial pain. CP would initially receive $200 million with an additional $475 million paid dependant on future milestones.
The acquisition is still subject to closing conditions from the UK and the US, including the waiting period required by the Hart-Scott-Rodino Antitrust Improvements Act from the US. The companies are not expecting any major difficulties and are hoping for the acquisition to clear within the first quarter of 2015.
Full Content: Post Online Media
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Google and South Carolina Clash Over State Records Demand
May 8, 2024 by
CPI
Telefonica Germany Teams Up with Amazon Web Services to Migrate 5G Customers
May 8, 2024 by
CPI
Federal Judge Grants $7.4 Million Settlement in Pork Price-Fixing Case
May 8, 2024 by
CPI
Wilson Sonsini Bolsters Antitrust and Competition Practice with Key Partner Returns
May 8, 2024 by
CPI
EU to Scrutinize Telecom Italia’s Network Sale to KKR
May 8, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI